Arcturus Therapeutics Holdings Inc.
ARCT
$14.74
-$0.89-5.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -89.54% | -92.99% | -68.39% | -58.84% | -43.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.54% | -92.99% | -68.39% | -58.84% | -43.24% |
| Cost of Revenue | -40.79% | -38.31% | -44.09% | -40.55% | -49.58% |
| Gross Profit | -1,038.97% | -253.22% | 17.77% | -340.80% | 85.49% |
| SG&A Expenses | 6.30% | -16.35% | 13.30% | -21.68% | -16.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.59% | -32.93% | -31.44% | -35.77% | -43.77% |
| Operating Income | -119.91% | -71.94% | 6.25% | -53.79% | 45.02% |
| Income Before Tax | -159.21% | -91.56% | 3.09% | -88.88% | 47.16% |
| Income Tax Expenses | -- | -- | 0.00% | -- | 102.67% |
| Earnings from Continuing Operations | -159.10% | -91.56% | 3.09% | -94.81% | 46.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -159.10% | -91.56% | 3.09% | -94.81% | 46.68% |
| EBIT | -119.91% | -71.94% | 6.25% | -53.79% | 45.02% |
| EBITDA | -129.79% | -76.43% | 5.99% | -60.30% | 46.40% |
| EPS Basic | -147.28% | -82.69% | 6.92% | -93.88% | 46.99% |
| Normalized Basic EPS | -147.40% | -82.74% | 6.92% | -88.02% | 47.48% |
| EPS Diluted | -147.28% | -82.69% | 6.92% | -93.88% | 46.99% |
| Normalized Diluted EPS | -147.40% | -82.74% | 6.92% | -88.02% | 47.48% |
| Average Basic Shares Outstanding | 4.77% | 4.85% | 4.12% | 0.47% | 0.60% |
| Average Diluted Shares Outstanding | 4.77% | 4.85% | 4.12% | 0.47% | 0.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |